Garuda Therapeutics seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Garuda's platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies. Like bone marrow transplants, Garuda's technology could provide potentially curative therapies for more than 70 diseases.
Location: United States, Massachusetts, Cambridge
Member count: 51-200
Total raised: $134M
Investors 2
| Date | Name | Website |
| 24.04.2022 | Aisling Ca... | aislingcap... |
| - | OrbiMed | orbimed.co... |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 07.02.2023 | Series B | $62M | Aisling Ca... | finsmes.co... |
| 23.09.2021 | Series A | $72M | - | aislingcap... |
Mentions in press and media 5
| Date | Title | Description | Category | Author | Source |
| 07.02.2023 | Garuda The... | Garuda Therapeutics, a Cambrid... | USA | - | finsmes.co... |
| 24.09.2021 | Garuda The... | Garuda Therapeutics, a Cambrid... | USA | - | finsmes.co... |
| 23.09.2021 | Garuda The... | CAMBRIDGE, MA, Garuda Therap... | - | - | vcnewsdail... |
| 23.09.2021 | Garuda The... | CAMBRIDGE, MA – September 23, ... | - | - | aislingcap... |
| - | Garuda The... | “Garuda – The Future of Blood ... | - | - | fastfounde... |